Massachusetts, USA-based IVREA Pharmaceuticals, an emerging specialty drugmaker focusing on dermatology, says it has raised $11.0 million from existing investors Atlas Venture and Easton Capital and new one CHL Medical Partners.
"Our existing investors and CHL Medical Partners recognize the immense potential of the two compounds we have in the clinic. Their support will enable IVREA to advance these two programs beyond Phase II clinical development," said Michael Kobos, the drug firm's chief executive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze